Diaphragm Hibernation and Its Driving Factors in Mechanically Ventilated ICU Patients (DISSECT)
Diaphragm hIbernation and itS Driving factorS in mEChanically venTilated ICU Patients: the DISSECT Study
Rationale:
Patients with invasive mechanical ventilation (IMV) frequently develop diaphragm dysfunction and experience difficult weaning. Recent ex vivo work suggests that a subset of mechanically ventilated ICU patients may exhibit diaphragm hibernation, an energy conserving myosin state that reduces force generation and may lead to a reversible increase in diaphragm strength over time. However, it is unknown whether diaphragm hibernation can be demonstrated in vivo during IMV and which clinical and biological factors are associated with this phenotype.
Objective:
Primary objective is to determine the driving factors (biomarkers) of diaphragm hibernation during IMV. Secondary objectives are to determine the proportion of ventilated critically ill patients who exhibit diaphragm hibernation during IMV, to investigate inflammatory and metabolic factors and other clinical exposures associated with diaphragm hibernation, and to explore associations between diaphragm hibernation and weaning related and survival outcomes.
Study design:
Prospective, observational, longitudinal cohort study.
Study population:
Adult ICU patients receiving IMV, expected to remain mechanically ventilated for at least 72 hours.
Intervention (if applicable):
Not applicable. This is an observational study. Study specific procedures consist of repeated phrenic nerve magnetic stimulation and additional blood sampling.
Main study parameters/endpoints:
The primary study parameter is the proportion of participants exhibiting diaphragm hibernation during IMV. Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0-1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death. Ptr,stim will be assessed repeatedly on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Participant burden is limited and mainly consists of repeated phrenic nerve magnetic stimulation during a ventilator delivered end expiratory occlusion and additional blood sampling of 9.5 mL per time point, up to a total of 47.5 mL across the study period. Magnetic stimulation is non-invasive and expected discomfort is transient. Rare transient physiological changes may occur and measurements are performed under continuous ICU monitoring and will be postponed or omitted if considered unsafe or interfering with clinical care. Direct benefit for participants is limited, but the study may provide clinically relevant knowledge on diaphragm hibernation and its driving factors. The research questions are specific to diaphragm physiology during IMV in critically ill patients, therefore the study is group related and cannot be performed in a different population.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Jinyu Zhou, M.sc.
- Telefonní číslo: 0031626194204
- E-mail: jinyu.zhou@radboudumc.nl
Studijní místa
-
-
Gelderland
-
Nijmegen, Gelderland, Holandsko, 6525 GA
- Radboud University Medical Center (Radboudumc)
-
Kontakt:
- Jonne Doorduin, PhD
- Telefonní číslo: 0031650155757
- E-mail: jonne.doorduin@radboudumc.nl
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Age ≥ 18 years.
- Receiving invasive mechanical ventilation at screening.
- Expected to remain mechanically ventilated for ≥ 72 hours from enrolment.
- The first study assessment can be performed within 36 hours after initiation of invasive mechanical ventilation.
Exclusion Criteria:
- Pre-existing neuromuscular disease affecting the diaphragm (e.g. motor neuron disease, myasthenia gravis, advanced muscular dystrophy, high cervical spinal cord injury) or use of neuromuscular blocker.
- Known phrenic nerve palsy or prior diaphragmatic paralysis.
- Long-term home mechanical ventilation (invasive or non-invasive) prior to ICU admission.
- Post-operative patients after planned diaphragm or phrenic nerve surgery.
- Contraindications to phrenic nerve magnetic stimulation (e.g., unstable cervical spine injury, uncontrolled intracranial hypertension, metallic implants in stimulation area as per manufacturer guidance).
- Pregnancy.
- Participation in another interventional trial that explicitly prohibits co-enrolment or is expected to substantially influence diaphragm function (e.g. experimental neuromuscular blocking strategies), as decided by the principal investigator.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
Patients with expected > 3 days of invasive mechanical ventilation
Patients expected > 3 days of invasive mechanical ventilation will be included in this study.
Blood sample and diaphragm strength will be assessed repeatedly, until 7 days after initiation of invasive mechanical ventilation, extubation or death.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Blood C reactive protein level
Časové okno: C reactive protein will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
C reactive protein will be assessed by blood sample.
|
C reactive protein will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood procalcitonin level
Časové okno: Procalcitonin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
Procalcitonin will be assessed by blood sample.
|
Procalcitonin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood metabolic biomarkers level
Časové okno: Metabolic biomarkers will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
Metabolic biomarkers will be assessed by blood sample using OLINK Target 96 panel.
|
Metabolic biomarkers will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood TNF-α level
Časové okno: TNF-α will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
TNF-α will be assessed by blood sample.
|
TNF-α will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood IL-10 level
Časové okno: IL-10 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
IL-10 will be assessed by blood sample.
|
IL-10 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood IL-8 level
Časové okno: IL-8 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
IL-8 will be assessed by blood sample.
|
IL-8 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood IL-6 level
Časové okno: IL-6 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
IL-6 will be assessed by blood sample.
|
IL-6 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Blood ferritin level
Časové okno: Ferritin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
Ferritin will be assessed by blood sample.
|
Ferritin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of participants exhibiting diaphragm hibernation during invasive mechanical ventilation
Časové okno: Ptr,stim will be assessed repeatedly on Day 0 to 1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0 to 1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death.
|
Ptr,stim will be assessed repeatedly on Day 0 to 1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
|
|
Number of days from intubation to successful extubation
Časové okno: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
Data about number of days from intubation to successful extubation will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
|
Number of days from first SBT to successful extubation
Časové okno: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
Data about number of days from first SBT to successful extubation will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
|
Incidence of weaning failure
Časové okno: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
Weaning failure is defined as SBT failure or reintubation within 48 hours.
Data will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
|
|
ICU length of stay
Časové okno: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
Data about ICU length of stay will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
|
Hospital length of stay
Časové okno: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
Data about hospital length of stay will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
|
ICU mortality
Časové okno: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
Data about ICU mortality will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
|
Hospital mortality
Časové okno: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
Data about hospital mortality will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
|
Day 28 all-cause mortality
Časové okno: Collected from study inclusion until Day 28 or death, whichever occurs first
|
Data about day 28 all-cause mortality will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28 or death, whichever occurs first
|
|
ICU-free days through day 28
Časové okno: Collected from ICU discharge until Day 28 or death, whichever occurs first
|
Data about ICU-free days through day 28 will be retrieved from electronic medical records.
|
Collected from ICU discharge until Day 28 or death, whichever occurs first
|
|
Hospital-free days through day 28
Časové okno: Collected from hospital discharge until Day 28 or death, whichever occurs first
|
Data about hospital-free days through day 28 will be retrieved from electronic medical records.
|
Collected from hospital discharge until Day 28 or death, whichever occurs first
|
|
Time to ICU discharge alive through day 28
Časové okno: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
Data about time to ICU discharge alive through day 28 will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
|
|
Time to hospital discharge alive through day 28
Časové okno: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
Data about time to hospital discharge alive through day 28 will be retrieved from electronic medical records.
|
Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Jonne Doorduin, PhD, Radboud University Medical Centre (Radboudumc)
- Studijní židle: Leo Heunks, M.D., PhD, Radboud University Medical Centre (Radboudumc)
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NL-011458
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .